CV Sciences, Inc. Experts Contribute to Journal of Dietary Supplements First Special Issue on Cannabinoids

SAN DIEGO, Aug. 13, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent leader in hemp-derived cannabidiol (CBD) products, is pleased to announce the publication of two papers in the Journal of Dietary Supplements’ first Special Issue on Cannabinoids. 

In this issue, CV Sciences’ team of physicians and scientists took the opportunity to contribute to the growing body of scientific evidence on hemp-derived CBD as a non-prescription product.

Dr. Douglas Mackay, N.D., Senior Vice President of Scientific and Regulatory Affairs for CV Sciences teamed up with Cannabis expert and academic Dr. Igor Koturbash, M.D., Ph.D., Associate Professor and Vice Chair of Environmental and Occupational Health at the Fay W. Boozman College of Public Health, University of Arkansas for Medical Sciences as co-editors of the Special Issue on Cannabinoids and provided the editorial, “Cannabidiol and Other Cannabinoids: From Toxicology and Pharmacology to the Development of a Regulatory Pathway." The editorial outlines the intent of the Special Issue on Cannabinoids, which is to address key scientific questions related to benefits, safety, and composition of popular hemp-derived CBD products.

Dr. Osvaldo Marinotti, Ph.D., Senior Scientist, CV Sciences, and Miles Sarill, M.Sc., National Educator for CV Sciences, co-authored, “Differentiating Full-Spectrum Hemp Extracts from CBD Isolates: Implications for Policy, Safety and Science.”

Both papers intended to add peer-reviewed scientific evidence that supports FDA’s request for “data that may help to address uncertainties and data gaps related to CBD, including real world evidence to address safety questions”.

Joseph Dowling, CV Sciences Chief Executive Officer, stated, “Observations from the food, supplement and cosmetic industries suggest that consumers expect a responsible, transparent, and science backed industry, that is fully FDA regulated. We agree with consumers, and that’s why we continue to lead the industry in advancing CBD science and regulatory compliance. We are proud to contribute our team’s expertise to this important cannabinoid report in the Journal of Dietary Supplements. These efforts help develop a framework for an FDA regulated industry that consumers can trust.”

The same Special Issue on Cannabinoids in the Journal of Dietary supplements also published the two previously announced research studies demonstrating the safety and health benefits of PlusCBD™ products:

Published on May 25, 2020, “Post Marketing Safety of Plus CBD™ Products, a Full Spectrum Hemp Extract: A 2-Year Experience,” this study adds to the growing body of literature that supports the safe use of hemp-derived CBD as a dietary supplement. The data confirm a low rate of adverse effects in millions of consumers taking PlusCBD™ products over a two-year period. A noteworthy finding was the absence of any reports of liver toxicity, which has been described in studies using high doses of CBD as a prescription drug.

Lead author Stephen Schmitz, MD, MPH and co-founder of Supplement Safety Solutions, stated, “This is the first longitudinal study of a CBD dietary supplement being used in real-world conditions. This study represents two years of data and daily product use from millions of consumers and demonstrates that CV Sciences’ products are safe and well tolerated.”

Published on May 27, 2020, “Effects of Hemp Extract on Markers of Wellness, Stress Resilience, Recovery and Clinical Biomarkers of Safety in Overweight, But Otherwise Healthy Subjects,” this study used PlusCBD™ products to determine their benefits on stress resilience, perceived recovery, mood, affect, body composition, and clinical safety markers in healthy human subjects.

Lead author Hector L. Lopez, M.D., CSCS, FAAPMR, FISSN, commented, “In a first of its kind study, participants taking PlusCBD™ products had significant improvement in HDL cholesterol compared to placebo, while improvements in measures of stress response, life pleasure, wellness and sleep were also observed. We also found an excellent safety profile, with no adverse signals in liver or other biomarkers of health in the group treated with PlusCBD™ products.”

Duffy MacKay, ND, Senior Vice President of Clinical and Regulatory Affairs for CV Sciences, stated, “These studies add to the growing evidence supporting the safety and benefits of hemp-derived CBD by tracking participant experience and health outcomes while taking CV Sciences’ proprietary CBD products. In 2018, CV Sciences achieved self-affirmed GRAS (Generally Recognized as Safe) status as a result of our extensive non-clinical testing program. Now, I am proud to say that CV Sciences is the only CBD company that has published toxicology studies, randomized, placebo-controlled clinical trials, and a systematic evaluation of post-market safety data of our products.”

The peer reviewed manuscripts created an opportunity for scientific and policy debate from a variety of expert viewpoints, including the article by P.S. Cogan, Ph.D., “Reality and Legality: Disentangling What is Actual from What is Tolerated in Comparison of Hemp Extracts with Pure CBD,” which suggested that hemp products with CBD are more appropriately regulated in alignment with current tobacco regulations. CV Sciences advocates that hemp-derived CBD products are dietary supplements, and we recognize that transparent public debate regarding these important issues are a critical component for sensible hemp-derived product regulations to be enacted.

About CV Sciences, Inc.

CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a consumer product division focused on manufacturing, marketing and selling plant-based dietary supplements and CBD products to a range of market sectors; and a drug development division focused on developing and commercializing CBD-based novel therapeutics. The Company’s PlusCBD™ products are sold at more than 6,300 retail locations throughout the U.S. and it is the top-selling brand of hemp-derived CBD in the natural product retail market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. CV Sciences follows all guidelines for Good Manufacturing Practices (GMP) and the Company’s products are processed, produced, and tested throughout the manufacturing process to confirm strict compliance with company standards and specifications. With a commitment to science, PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PlusCBD™ was the first hemp CBD supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. CV Sciences, Inc. has primary offices and facilities in San Diego, California. Additional information is available from or by visiting


This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

Investor Contact:
Scott Van Winkle

Media Contact:
Cory Ziskind


Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.